Luyckx VA, Cherney D, Bello AK
doi:10.1016/j.bbadis.2011.06.004 Klooker TK, Braak B, Koopman KE, et al
Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
I T DIDNT HAPPEN overnight, but Wes Turner says his wife turned him on to a life-changing habit
We are talking about a 29 to 31 gauge needle, roughly the width of a human hair